Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy - ILCN.org (ILCN/WCLC)

Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy - ILCN.org (ILCN/WCLC)

Activating HER2 mutations occur in 2% to 4% of patients with non-small cell lung cancer (NSCLC). Patients harboring such mutations often have a worse prognosis and higher incidence of brain metastases. John V. Heymach, MD, PhD “There remains a clear, unmet need for a potent TKI that selectively inhibits HER2 while sparing these EGFR-related toxicities,” said John V. Heymach, MD, PhD, Chair of Thoracic, Head, and Neck Medical Oncology and a Prof…